2-p-Chlorophenyl-2,3,6,7,8,9-hexahydropyrazolo[4,3-c][1,6]naphthyridin-3(5H)-one | 102200-12-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-p-Chlorophenyl-2,3,6,7,8,9-hexahydropyrazolo[4,3-c][1,6]naphthyridin-3(5H)-one
• CAS: 102200-12-4
• 化学式: C₁₅H₁₃ClN₄O
• 分子量: 300.747
• InChiKey: ZCLSMKKSYSHVET-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.96
• 重原子数：
  21.0
• 可旋转键数：
  1.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  62.71
• 氢给体数：
  2.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  2-p-Chlorophenyl-2,3,6,7,8,9-hexahydropyrazolo[4,3-c][1,6]naphthyridin-3(5H)-one 生成 8-acetyl-2-p-chlorophenyl-2,3,6,7,8,9-hexahydropyrazolo[4,3-c][1,6]naphthyridin-3(5H)-one
  参考文献：
  名称：

  Ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives as benzodiazepine

  摘要：

  公式IA或IB的化合物其中A代表可选择取代的饱和双价基团，与其连接的两个碳原子一起表示从可选择取代的融合环中选择的5、6或7元碳环或杂环，包括可选择取代的融合环戊烯、环己烯、环庚烯、二氢噻吩、二氢噻吡喃、四氢噻吩、二氢呋喃、二氢吡喃、四氢氧吩、二氢吡咯、四氢吡啶和四氢氮杂二氢吡喃; R1代表低碳基、苯基，或由低碳基、低碳氧基、卤素或三氟甲基单取代或双取代的苯基; 或R1代表芳香杂环基团，例如可选择取代的吡啶基、喹啉基、异喹啉基、嘧啶基和噻唑基; R2、R3、R3'为氢或低碳基; 和药学上可接受的盐; 用作治疗神经系统疾病的苯二氮卓受体调节剂。还公开了作为苯二氮卓受体调节剂有用的药物组合物、制备方法和某些中间体。

  公开号：

  US04602014A1
• 作为产物：
  描述：

  ethyl 6-ethoxycarbonyl-4-chloro-5,6,7,8-tetrahydro[1,6]naphthyridine-3-carboxylate 在 氢溴酸 、 溶剂黄146 作用下， 以 正丁醇 为溶剂， 生成 2-p-Chlorophenyl-2,3,6,7,8,9-hexahydropyrazolo[4,3-c][1,6]naphthyridin-3(5H)-one
  参考文献：
  名称：

  2,5-Dihydropyrazolo[4,3-c]pyridin-3-ones: functionally selective benzodiazepine binding site ligands on the GABAA receptor

  摘要：

  2,5-Dihydropyrazolo[4,3-c]pyridin-3-ones are GABA(A) receptor benzodiazepine binding site ligands with functional selectivity for the alpha(3) subtype over the alpha(1) subtype. SAR studies to optimise this functional selectivity are described. (C) 2004 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2004.04.085

文献信息

• Treating anxiety with certain ring-fused pyrazolo[3,4-d]-pyridin-3-one
  申请人：Ciba-Geigy Corporation

  公开号：US04740512A1

  公开（公告）日：1988-04-26

  Compounds of the formula IA or IB ##STR1## wherein A represents an optionally substituted saturated divalent grouping which together with the two carbon atoms to which it is attached represents a fused 5-, 6- or 7-membered carbocyclic or heterocyclic ring selected from optionally substituted fused cyclopenteno, cyclohexeno, cyclohepteno, dihydrothieno, dihydrothiopyrano, tetrahydrothiepino, dihydrofuro, dihydropyrano, tetrahydrooxepino, dihydropyrrolo, tetrahydropyrido and tetrahydroazepino; R.sub.1 represents lower alkyl, phenyl, or phenyl mono- or disubstituted by lower alkyl, lower alkoxy, halogen or trifluoromethyl; or R.sub.1 represents an aromatic heterocyclic radical selected from e.g. optionally substituted pyridyl, quinolyl, isoquinolyl, pyrimidyl and thiazolyl; R.sub.2, R.sub.3, R.sub.3 ' are hydrogen or lower alkyl; and pharmaceutically acceptable salts; are useful as benzodiazepine receptor modulators for the treatment of nervous system disorders. Pharmaceutical compositions, methods of preparation and certain intermediates useful as benzodiazepine receptor modulators are also disclosed.

  式IA或IB的化合物，其中A代表一个可选择替代的饱和二价基团，与其连接的两个碳原子一起代表一个选择自可选择替代的融合环的5、6或7成员碳环或杂环，包括可选择替代的融合环己烯、环己烯、环庚烯、二氢噻吩、二氢硫吡喃、四氢噻吩、二氢呋喃、二氢吡喃、四氢氧吡喃、二氢吡咯、四氢吡啶和四氢氮杂环; R.sub.1代表低碳烷基、苯基，或者被低碳烷基、低碳氧基、卤素或三氟甲基单取代或双取代的苯基; 或者R.sub.1代表芳香杂环基，例如可选择替代的吡啶基、喹啉基、异喹啉基、嘧啶基和噻唑基; R.sub.2、R.sub.3、R.sub.3'为氢或低碳烷基; 和药用盐; 用作治疗神经系统疾病的苯二氮卓类受体调节剂。还公开了作为苯二氮卓类受体调节剂有用的药物组合物、制备方法和某些中间体。
• Certain ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives in treating
  申请人：Ciba-Geigy Corporation

  公开号：US04647566A1

  公开（公告）日：1987-03-03

  Compounds of the formula formula IA or IB ##STR1## wherein A represents an optionally substituted saturated divalent grouping which together with the two carbon atoms to which it is attached represents a fused 5-, 6- or 7-membered carbocyclic or heterocyclic ring selected from optionally substituted fused cyclopenteno, cyclohexeno, cyclohepteno, dihydrothieno, dihydrothiopyrano, tetrahydrothiepino, dihydrofuro, dihydropyrano, tetrahydrooxepino, dihydropyrrolo, tetrahydropyrido and tetrahydroazepino; R.sub.1 represents lower alkyl, phenyl, or phenyl mono- or disubstituted by lower alkyl, lower alkoxy, halogen or trifluoromethyl; or R.sub.1 represents an aromatic heterocyclic radical selected from e.g. optionally substituted pyridyl, quinolyl, isoquinolyl, pyrimidyl and thiazolyl; R.sub.2, R.sub.3, R.sub.3 ' are hydrogen or lower alkyl; and pharmaceutically acceptable salts; are useful as benzodiazepine receptor modulators for the treatment of nervous system disorders. Pharmaceutical compositions, methods of preparation and certain intermediates useful as benzodiazepine receptor modulators are also disclosed.

  化合物的结构式为IA或IB，其中A代表可选择地取代的饱和双价基团，与其连接的两个碳原子一起代表从可选择取代的融合环戊烯、环己烯、环庚烯、二氢噻吩、二氢噻吩吡喃、四氢噻环戊、二氢呋喃、二氢吡喃、四氢氧杂环戊、二氢吡咯、四氢吡啶和四氢氮杂环庚中选择的融合5、6或7-成员碳环或杂环环; R1代表低碳烷基、苯基，或由低碳烷基、低碳氧基、卤素或三氟甲基单取代或双取代的苯基; 或R1代表选择自例如可选择取代的吡啶基、喹啉基、异喹啉基、嘧啶基和噻唑基的芳香杂环基; R2、R3、R3'为氢或低碳烷基; 和药学上可接受的盐; 用作治疗神经系统疾病的苯二氮卓类受体调节剂。还公开了作为苯二氮卓类受体调节剂有用的药物组合物、制备方法和某些中间体。
• Certain ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives
  申请人：Ciba-Geigy Corporation

  公开号：US04814450A1

  公开（公告）日：1989-03-21

  Compounds of the formula formula IA or IB ##STR1## wherein A represent an optionally substituted saturated divalent grouping which together with the two carbon atoms to which it is attached represents a fused 5-, 6- or 7-membered carbocyclic or heterocyclic ring selected from optionally substituted fused cyclopenteno, cyclohexeno, cyclohepteno, dihydrothieno, dihydrothiopyrano, tetrahydrothiepino, dihydrofuro, dihydropyrano, tetrahydrooxepino, dihydropyrrolo, tetrahydropyrido and tetrahydroazepino; R.sub.1 represents lower alkyl, phenyl, or phenyl mono- or disubstituted by lower alkyl, lower alkoxy, halogen or trifluoromethyl; or R.sub.1 represents an aromatic heterocyclic radical selected from e.g. optionally substituted pyridyl, quinolyl, isoquinolyl, pyrimidyl and thiazolyl; R.sub.2, R.sub.3, R.sub.4 ' are hydrogen or lower alkyl; and pharmaceutically acceptable salts; are useful as benzodiazepine receptor modulators for the treatment of nervous system disorders. Pharmaceutical compositions, methods of preparation and certain intermediates useful as benzodiazepine receptor modulators are also disclosed.

  式IA或IB的化合物##STR1##其中A代表一个可以选择性取代的饱和二价基团，与其相连的两个碳原子共同代表一种选择自可选择性取代的融合的5-,6-或7-成员碳环或杂环，所述环选自可选择性取代的融合的环戊烯基，环己烯基，环庚烯基，二氢噻吩基，二氢噻吩并吡喃基，四氢噻环并吡喃基，二氢呋喃基，二氢吡喃基，四氢氧环并吡喃基，二氢吡咯基，四氢吡啶基和四氢氮杂环并吡喃基；R.sub.1代表较低的烷基，苯基，或被较低的烷基，较低的烷氧基，卤素或三氟甲基单取代或双取代的苯基；或R.sub.1代表选自例如可选择性取代的吡啶基，喹啉基，异喹啉基，嘧啶基和噻唑基的芳香族杂环基；R.sub.2，R.sub.3，R.sub.4'为氢或较低的烷基；以及药学上可接受的盐；用作苯二氮平受体调节剂，用于治疗神经系统疾病。还公开了制药组合物，制备方法和某些中间体，这些中间体用作苯二氮平受体调节剂。
• Certain ring-fused pyrazolo [3,4-d]-pyridin-3-one derivatives
  申请人：CIBA-GEIGY AG

  公开号：EP0168350A2

  公开（公告）日：1986-01-15

  Compounds of the formula IA or IB wherein A represents an optically substituted saturated divalent grouping which together with the two carbon atoms to which it is attached represents a fused 5-, 6- or 7- membered carbocyclic or heterocyclic ring selected from optionally substituted fused cyclopenteno, cyclohexeno, cyclohepteno, dihydrothieno, dihydrothiopyrano, tetrahydrothiepino, dihydrofuro, dihydropyrano, tetrahydrooxepino, dihydropyrrolo, tetrahydropyrido and tetrahydroazepino; R, represents lower alkyl, phenyl, or phenyl mono- or disubstituted by lower alkyl, lower alkoxy, halogen or trifluoromethyl; or R1 represents an aromatic heterocyclic radical selected from e.g. optionally substituted pyridyl, quinolyl, isoquinolyl, pyrimidyl and thiazolyl; R2, R3, R3' are hydrogen or lower alkyl; and pharmaceutically acceptable salts; are useful as benzodiazepine receptor modulators for the treatment of nervous system disorders. Pharmaceutical compositions, methods of preparation and certain intermediates useful as benzodiazepine receptor modulators are also disclosed.

  式 IA 或 IB 的化合物 其中 A 代表被光学取代的饱和二价基团，该基团与所连接的两个碳原子一起代表一个融合的 5、6 或 7 位碳环或杂环，该环可选自任选取代的融合环戊烯基、环己烯基、环庚烯基、二氢噻吩基、二氢噻喃基、四氢噻吩基、二氢噻吩基二氢噻吩酮、二氢硫吡喃酮、四氢硫杂环酮、二氢呋喃酮、二氢吡喃酮、四氢氧杂环酮、二氢吡咯酮、四氢吡啶酮和四氢氮杂环酮；R，代表低级烷基、苯基或由低级烷基、低级烷氧基、卤素或三氟甲基单取代或二取代的苯基；或 R1 代表芳香杂环基，选自如 下化合物g.任选取代的吡啶基、喹啉基、异喹啉基、嘧啶基和噻唑基；R2、R3、R3'为氢或低级烷基；以及药学上可接受的盐；可用作苯并二氮杂卓受体调节剂，用于治疗神经系统疾病。此外，还公开了用作苯二氮卓受体调节剂的药物组合物、制备方法和某些中间体。
• YOKOYAMA, NAOKATA
  作者：YOKOYAMA, NAOKATA

  DOI：——

  日期：——